Navigation Links
NanoViricides' Anti-Virus Technology Published in Handbook of Clinical Nanomedicine
Date:2/22/2016

SHELTON, Conn., Feb. 22, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC (the "Company") announced today that information on its novel, proprietary anti-virus platform technology has been published in the book "Handbook of Clinical Nanomedicine, Vol. 1. Nanoparticles, Imaging, Therapy, and Clinical Applications", a CRC Press publication. The chapter entitled "Nanoviricides: Targeted Anti-Viral Nanomaterials" provides an in-depth presentation of the NanoViricides platform technology, evidence for how nanoviricides® are believed to act plus dramatic results of nanoviricides specifically targeting certain viral diseases, such as Influenza.

This chapter introduces the novel NanoViricides nanotechnology that possesses potent antiviral efficacy by targeting the mechanisms by which viruses attach or bind to cells.  A nanoviricide is believed to act like a decoy of a human cell. When the virus sees the appropriate mimic of its cell binding site displayed on a nanoviricide, the virus binds to it. The Company believes that the flexible nanoviricide enables cooperative binding of the nanoviricide to additional sites on the virus surface in a velcro-like effect. This maximization of virus binding would lead to the nanoviricide  spreading onto the virus particle, fusing with the virus surface, and then engulfing the virus. In the process, the coat proteins that the virus uses for binding to cells would be expected to become unavailable, and could fall off the virus surface.  This highly targeted attack would lead to the loss of the viral coat proteins and the nanoviricide may further dismantle the engulfed virus capsid.  The loss of virus particle integrity would neutralize the virus, making the virus non-infectious.

The Handbook of Clinical Nanomedicine, Vol. 1. Nanoparticles, Imaging, Therapy, and Clinical Applications, edited by Raj Bawa, PhD, Gerald F. Audette, PhD, and Israel Rubinstein, MD, is the first volume in a two volume set published by CRC Press; it is part of the Pan Stanford Series on Nanomedicine. The publisher states that Volume 1 "provides a comprehensive roadmap of basic research in nanomedicine as well as clinical applications. It not only highlights current advances in diagnostics and therapies but also explores related issues like nomenclature, terminology, historical developments, and regulatory aspects. While bridging the gap between basic biomedical research, engineering, medicine and law, the handbook provides a thorough understanding of nano's potential to address (i) medical problems from both the patient and health provider's perspective, and (ii) current applications and their potential in a healthcare setting." The CRC Press lists the official publication date as February 28, 2016. (https://www.crcpress.com/Handbook-of-Clinical-Nanomedicine-Two-Volume-Set/Bawa-Audette-Rubinstein/9789814316170).

About NanoViricides:  
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

Logo - http://photos.prnewswire.com/prnh/20150107/167444LOGO


'/>"/>
SOURCE NanoViricides, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. NanoViricides CEO to Present at the 18th Annual BIOCEO & Investor Conference on February 8, 2016 and at the Disruptive Growth and Healthcare Conference on February 11, 2016, both in New York City
2. NanoViricides Issued Registered Shares as Interest to Certain Debenture Holders
3. New Medical Technology Hits the High Seas Exploring Low Oxygen Waters
4. Erlab’s GreenFumeHood Filtration Technology plays a major role in the Zero Net Energy equation for Bristol Community College
5. Pharmaceutical And Biotechnology Patent Expert John Doll Joins Viropro Board
6. Proove Biosciences Highlights Personalized Medicine Technology as an Approach to Reduce Prescription Drug Abuse
7. BD Unveils New Next Generation Sequencing Library Prep System at the 2016 Advances in Genome Biology and Technology Meeting
8. Beike Biotechnology to Supply 11 Hospitals in Shenzhen, China with Cell Therapy
9. AllegroGraph Recognized by Corporate America Magazine as Best in Semantic Web Technology - USA & Leader in Graph Database Products
10. Symphony Technology Group Announces Sale of AlphaImpactRx to IMS Health
11. Vital Force Technology Announces New Formulas for Improving the Bioavailability of Functional Beverages
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2018)... ... 04, 2018 , ... Karius , a life sciences ... at IDWeek™ 2018 the positive results of a study demonstrating that the Karius® ... causative pathogens in patients with infective endocarditis even when blood cultures were negative ...
(Date:10/2/2018)... ... October 02, 2018 , ... Finalists for the 2018 ... AssurEOR product line was chosen for its advancements in the production chemicals category. ... innovations in upstream oil applications that are positively impacting the industry. The winners ...
(Date:9/28/2018)... ... 28, 2018 , ... LabRoots , the leading provider ... around the world, is excited to announce Daniel Andrade, a 22-year-old undergraduate student ... of the LabRoots Summer 2018 Textbook Scholarship, awarding him $1,000 to support him ...
(Date:9/27/2018)... ... September 27, 2018 , ... ... Health Solutions and SureAdhere Mobile Technology, Inc. announced they will formally merge companies ... the battle against tuberculosis (TB) and other diseases. These two social enterprise corporations, ...
Breaking Biology Technology:
(Date:10/5/2018)... ... ... Nothing brings a team together like cooking and eating does, which is why ... companies because it encourages a range of healthy activities that can translate into the ... appealing in that everyone – no matter their culinary ability – can participate. ...
(Date:10/2/2018)... ... October 02, 2018 , ... Stuart is a fun-loving eight-year-old Labrador retriever. Like many labs, ... Cynthia, “He loves playing ball so much that whenever anyone comes to our door, he ... game of fetch.” In early 2017, Stuart began limping and eventually could no longer ...
(Date:10/1/2018)... Mont. (PRWEB) , ... October 01, 2018 , ... ... company advancing targeted antibody drug conjugate (ADC) like, lipid based therapeutics, today announced ... (SBIR) Program had confirmed the award of first year funding for two ...
Breaking Biology News(10 mins):